Lung Hyperinflation and Response to Pulmonary Vasodilator Therapy

Central Hospital, Nancy, France47 enrolled

Overview

The goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). The study will include all patients from the hospital, followed for pulmonary hypertension associated with COPD under vasodilator therapy between 2015 and 2021.

The goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). The study will include all patients from the hospital, followed for PH associated with COPD under vasodilator therapy between 2015 and 2021. It will evaluate patients' lung hyperinflation according to the RV/TLC ratio and their response to treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Copd Hypertension, Pulmonary Hyperdistention

Interventions

Respiratory function tests before introduction of vasodilator therapyDIAGNOSTIC_TEST

Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.

3 month follow up evaluation of response to treatment.DIAGNOSTIC_TEST

Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with COPD regardless of severity defined as a FEV1/FVC ratio less than 0.70 and the presence of a risk factor (smoke exposure with at least a 10 pack-year history, or professional exposition) diagnosed with PH according to ESC/ERS 2022 classification and in whom vasodilator therapy has been initiated Exclusion Criteria: * other known concomitant lung disease (interstitial lung disease, cystic lung disease, mucoviscidosis…) * thoracic pathology such as kyphoscoliosis * pleural effusion (unless part of pulmonary veno-occlusive disease) * a large tumor lung mass * EFR missing or uninterpretable because difficult to perform * initiation of calcium channel blockers * surgical treatment in chronic thrombo-embolic pulmonary hypertension * no follow-up evaluation (lost to follow-up or died before reassessment)

Locations (1)

CHU Nancy

Vandœuvre-lès-Nancy, France

Outcomes

Primary Outcomes

Response to treatment

Response to treatment is defined as an improvement of at least 30 meters in the 6-minute walk test or one NYHA functional class at the first re-evaluation performed at least 3 months after the initiation of vasodilator therapy. These criteria will be compared according to the severity of chest distension.

Time frame: 3 - 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.